Latest Post

May 22, 2018no comments

Forget about greed, President Trump: the villain responsible for high drug prices is inefficiency

Endpoints article

“I have directed my administration to make fixing the injustice of high drug prices one of my top priorities.”
– President Donald Trump
2018 State of the Union address

Directing people to fix problems ...

Read More

SCIENTIFIC SUPPOSITIONS

Contact DrugBaron and Subscribe for a weekly digest of new postsNews, musings & opinions from the pen of the Drug Baron, Cambridge

Drug Baron Blog

Latest Post

May 22, 2018 no comments

Forget about greed, President Trump: the villain responsible for high drug prices is inefficiency

Endpoints article

“I have directed my administration to make fixing the injustice of high drug prices one of my top priorities.”
– President Donald Trump
2018 State of the Union address

Directing people to fix problems is one thing, but actually fixing them is quite another. And while President Trump may see high drug prices as an “injustice”, the evidence that corporate greed is to blame is patchy at best. The truth is, there’s a complex set of factors at work behind high drug prices. And taking the time to understand it has to be the essential first step towards identifying the true villain and then “fixing” the problem.

 

First, while US healthcare costs are already a global outlier at around $10,000/person annually, and still rapidly growing, drugs of all kinds including OTCs represent approximately 14% of the total bill.  By far the largest contributor to costs are hospital and physician fees.  As a result, even halving drug costs (which is as impossible as it is undesirable) would fail to lower US healthcare spending to level of the next most profligate country — tiny Luxemburg.  If the President wants to address healthcare spending, he needs to take on physicians, not pharma companies, when he returns to the subject in his forthcoming speech.

 

If we narrow the focus just to the cost of drugs, we still do not see egregious inflation.  Annual growth in drug costs has been below 5% a year for the last decade, such that the proportion of healthcare spending on drugs is actually falling. That’s because hospital and physician costs grow faster.

 

If those are the figures, why then is there a perception of over-priced drugs? Let’s explore the reasons:

 

Bad actors are cheating the system by offering old, cheap drugs at exorbitant prices

 

The tale of Martin Shkreli’s ill-fated price hike for daraprim, an aging AIDS and cancer med sold by Turing Pharmaceuticals, made headline news but these brazen attempts to exploit the barriers created by the regulatory framework around prescription medicines have no meaningful impact on the overall drugs bill.  Of course we should take action to prevent consumers and taxpayers being exploited in this way, but we should not generalize the problem.

 

New drugs are launched with massive and unjustifiable price tags

 

Neither, too, do the introduction of new medicines, often with eye-watering price tags, contribute to runaway healthcare costs.  Indeed, the focus on the prices of these successful innovations is the most frustrating aspect of the debate.  Most egregious was the ire directed at Gilead following the launch of Sovaldi with a headline price of $84,000 for a course of pills that, in almost every patient, could cure …

More

Yearly Archive

Useful Resources

Discovering and developing drugs according to the “asset-centric” strategy depends entirely on the availability of high quality out-sourced service providers, who not only deliver the R&D infra-structure for small and virtual biotech companies, but who understand the essential differences between “asset-centric” R&D and the classical model. DrugBaron has founded and worked for more than a dozen asset-centric companies over the last decade, developing both small molecules and biologics in a wide range of indications. That experience has identified those service providers (usually smaller than the global brands) who understand “asset-centric” R&D and who can support new companies adopting this strategy.  Those are the companies listed here.

The Cambridge Partnership is the only professional services company in the UK exclusively dedicated to supporting companies in the biotechnology industry. We specialize in providing a “one-stop shop” for accountancy, company secretarial, IP management and admin services.

Accounting & Back-Office Services

A professional services company exclusively dedicated to supporting companies within the biotechnology industry.

RxCelerate Ltd is an outsourced drug development platform based near Cambridge, UK. We specialize in delivering an entire road map of drug development services from discovery and medicinal chemistry through to preclinical and clinical Phase IIa.

Out Sourced Drug Developer

Specialising in delivering an entire road map of drug development services from discovery through to preclinical/clinical Phase IIa.

SEND & SUBSCRIBE

Contact DrugBaron and Subscribe for a weekly digest of new posts

Contact Us

EMAIL
drugbaron@rxcelerate.com

RxCelerate UK
Babraham Research Campus
Babraham
Cambridge CB22 3AT
United Kingdom